Advancing Innovative Therapeutic Solutions Targeting Inflammatory and Neurological Disorders

Learn More

Our research goal is to develop drugs that treat chronic inflammatory conditions while minimizing the side-effects commonly associated with current anti-inflammatory medications. We are also developing treatments for neurologic conditions such as smoking addiction. We work both independently and with academic and industry thought leaders to develop novel medications that will treat these underserved patient populations. We currently have a number of drugs in development which target these therapeutic areas.

Research and Development
Dr. Michael Mullan, Chairman and CEO of Rock Creek Pharmaceuticals: This is a pivotal moment in the history of our company. Our ongoing transition reflects the new strategic focus of the company to fully exploit its current and emerging technologies by developing drug products to reduce the medical burden of chronic inflammatory disorders and nicotine addiction.
Learn more about Dr. Mullan and the executive team. →